BCMA-Targeting Strategies Transform Multiple Myeloma Treatment

Jessica Hergert
Published: Wednesday, Dec 04, 2019
Saad Z. Usmani, MD, FACP, chief of the Plasma Cell Disorders Program and director of clinical research in hematologic malignancies at Levine Cancer Institute

Saad Z. Usmani, MD, FACP

The development of monoclonal antibody–based therapies is changing the landscape of multiple myeloma, said Saad Z. Usmani, MD, FACP, in the form of various BCMA-targeting modalities.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication